Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

NCT02719613 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Elotuzumab
DRUG: Dexamethasone
DRUG: Dexamethasone
DRUG: Lenalidomide
DRUG: Bortezomib
DRUG: Pomalidomide
DRUG: Nivolumab

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]